Katherine Goodrich, serving as a director for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), has completed a transaction involving the sale of 2,954 shares of the company's common stock. Executed on June 15, 2026, the total value of this sale reached $183,384. The shares were disposed of at a price of $62.08 per share. This specific transaction was structured as an automatic sale under a Rule 10b5-1 trading plan, a framework that Ms. Goodrich established on February 27, 2026. Following the completion of this sale, Ms. Goodrich's direct ownership stake in Tarsus Pharmaceuticals common stock stands at 2,233 shares.
This insider activity unfolds against the backdrop of Tarsus Pharmaceuticals' current market positioning. The company's shares are currently trading in the vicinity of $62.55. Over the trailing twelve-month period, the stock has delivered a substantial 54% return, although this performance has been accompanied by recent volatility. Tarsus Pharmaceuticals maintains a market capitalization of $2.68 billion. Analysis from InvestingPro indicates that the stock is currently trading close to its Fair Value. Investors interested in deeper insights may access comprehensive Pro Research Reports, which cover TARS and over 1,400 US equities, offering additional exclusive ProTips.
In a broader context, Tarsus Pharmaceuticals recently reported its Q1 2026 earnings results, which surpassed analyst expectations. The company reported an earnings per share (EPS) of -$0.16, representing a significant improvement over the anticipated -$0.30. This resulted in a positive surprise of 46.67%. Furthermore, Tarsus Pharmaceuticals reported revenue of $162 million, exceeding the forecasted $153.12 million. Despite these strong financial results, the company's stock experienced a slight decline in aftermarket trading. Analysts have noted the company's performance, with some firms evaluating the implications of these earnings on future projections. Investors may find these recent developments noteworthy as they assess the company's financial health. The earnings report highlights Tarsus Pharmaceuticals' ability to outperform market expectations, which could influence analyst ratings in the near future.